<DOC>
	<DOCNO>NCT00067626</DOCNO>
	<brief_summary>The purpose study investigate effect Chromium glucose tolerance endothelial function people risk type II diabetes .</brief_summary>
	<brief_title>Chromium Effects Insulin Vascular Function People Risk Diabetes</brief_title>
	<detailed_description>Impaired glucose tolerance ( IGT ) , impaired fasting glucose ( IFG ) , insulin resistance ( IR ) precursor type II diabetes mellitus ( DM ) sequela , cardiac risk factor right . The worsen epidemic DM US , along increase prevalence obesity , insulin resistance , IGT , render identification promise intervention state matter urgency . While lifestyle intervention base dietary pattern physical activity delay prevent onset diabetes , reduce cardiovascular risk , adherence population level severely limit . Pharmacotherapy offer promise diabetes prevention , associate high cost , unacceptability many patient , potential toxicity . In context , potential role chromium ( Cr ) , insulin co-factor , IGT great interest . Chromium use widespread , evidence therapeutic effect limit . Proposed , therefore , randomize , double-blind , placebo control pilot trial conduct Yale Prevention Research Center , investigate effect daily Cr 6 month two dose level serum measure glucose tolerance , endothelial function , adult IGT , IFG , IR . A modify crossover design allow pair unpaired analysis include comparison 500 mcg 1,000 mcg Cr daily placebo ; comparison 500 mcg 1000 mcg chromium ; evaluation Cr washout time . The study power detect clinically meaningful effect Cr supplementation either dose glucose control , compare two dos equivalence . The study investigate effect Cr measure glucose tolerance ( glucose , insulin , OGTT ) brachial artery endothelial function , thus combine serum measure physiologic test Cr effect vasculature . The propose study generate much need data regard efficacy Cr risk type II diabetes offer promise guide practice , well direct future study . By contribute knowledge relate potential diabetes prevention strategy , study address one press public health issue US today . Risk human subject study minor increment minimal due administration nitroglycerin control BARS testing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Adults 18 year age old Identified impair glucose tolerance ( IGT ) , impaired fasting glucose ( IFG ) , insulin resistance . According 1999 World Health Organization ( WHO ) report , IGT diagnose follow two criterion meet : 1 ) Plasma glucose two hour consume 75g glucose ( OGTT ) least 7.8 mmol/l ( 140 mg/dl ) 11.1 mmol/l ( 200 mg/dl ) 2 ) Fasting plasma glucose level less 7.0 mmol/l ( 126 mg/dl ) . IFG diagnose fast plasma glucose concentration 5.6 mmol/l ( 100 mg dl/l ) great , less 7.0 mmol/l ( 126 mg dl/l ) . NCEP ATP III guideline define 5 component insulin resistance . At least 3 5 criterion require diagnosis . These component : Abdominal obesity determine waist circumference &gt; 102cm ( &gt; 40in ) men &gt; 88cm ( &gt; 35in ) woman ; triglyceride level ≥150mg/dL ; HDLC &lt; 40mg/dL men &lt; 50mg/dL woman ; blood pressure ≥ 130/≥85mm Hg ; fast glucose ≥ 100mg/dL . Connecticut resident willing travel Griffin Hospital Derby , CT Known diabetes ( Fasting Plasma Glucose &gt; 126 mg/dl ; 2hour 75g OGTT plasma glucose &gt; 200 mg/dl ; Diabetes diagnosed physician confirm clinical data ) ; Selfreported hospitalization treatment heart disease past 6 month ; Impaired renal function measure labwork initial screening ( serum creatinine great 2.0 Serum creatinine urine albumin excretion test every six month throughout study ) . Significant change baseline outside threshold report DSMB appropriate action , include removal study . Selfreported pancreatitis . In instance potential subject report unsure whether diagnosed condition , primary medical doctor 's note obtain confirm nondiagnosis inclusion study . Selfreported recent significant abdominal surgery ; Selfreported pregnancy and/or intention become pregnancy study . Women childbearing age consent pregnancy test baseline , agree avoid pregnancy reliable mean throughout duration study . Selfreported polycystic ovarian syndrome irregular menses exclude study . ( In future , people selfreported polycystic ovarian syndrome irregular menses may allow study , however , condition potential affect outcome BARS testing ( secondary outcome ) , treat subset population data analysis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>glucose tolerance test</keyword>
	<keyword>mineral</keyword>
	<keyword>chromium</keyword>
	<keyword>complementary alternative medicine</keyword>
</DOC>